Johnson & Johnson is reportedly discussing the purchase of Protagonist Therapeutics. This move could boost J&J's drug portfolio, especially in treatments for immune conditions and blood cancers.
President Trump is hitting imports with massive new tariffs starting October 1st, targeting branded drugs (100%), heavy trucks (25%), and furniture.
JNJ-1900 offers new hope for advanced melanoma patients whose cancer progressed after many treatments, including anti-PD-1. Injected into tumors, activated by radiation, then combined with anti-PD-1, it shows promising early safety and efficacy signals, potentially boosting the immune system.
